Multi-Target Ligands Design and Targeted Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 93
Special Issue Editors
Interests: drug design; medicinal chemistry; epigenetic inhibitors; multitarget ligands; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; drug design; multitarget ligands
Special Issue Information
Dear Colleagues,
In drug design for multifactorial diseases such as cancer and neurodegenerative disorders, the "one molecule, one target" approach is generally considered to be too simplistic, leading to low efficacy and safety. Therefore, modern drug design aims to develop a single drug molecule that can interact simultaneously and specifically with two or more targets, or to design ligand-targeted drug delivery systems as a new strategy to improve efficacy and safety and reduce side effects. The rational design of multi-target ligands and ligand-targeted drug delivery systems remains a challenge, both in terms of disease-specific target selection and small molecule discovery. In addition, pharmacokinetic properties, balanced activity, and selectivity are important factors that should be optimized in the development of multi-target drugs and ligand-targeted drug delivery systems.
This Special Issue presents innovations in the field of multi-target ligand development. These include various chemoinformatic methods that enable prediction of the primary pharmaceutical target and off-targets of compounds, computational methods for their rational drug design, advanced synthesis techniques, and biological evaluation.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Design, synthesis and biological evaluation of multi-target ligands for cancer and neurodegenerative diseases;
- Identification of novel drug targets and signaling molecules in multifactorial diseases;
- Targeted drug delivery systems for innovative therapy of complex diseases.
We look forward to receiving your contributions.
Prof. Dr. Katarina Nikolić
Dr. Slavica Oljacic
Dr. Marija Popovic Nikolic
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug design
- multi-target ligands
- targeted drug delivery
- kinases
- epigenetics
- cancer
- neurodegeneration
